PMID- 37465496
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230720
IS  - 2222-3959 (Print)
IS  - 2227-4898 (Electronic)
IS  - 2222-3959 (Linking)
VI  - 16
IP  - 7
DP  - 2023
TI  - Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic 
      injection in the treatment of macular edema caused by retinal vein occlusion: a 
      Meta-analysis.
PG  - 1145-1154
LID - 10.18240/ijo.2023.07.21 [doi]
AB  - AIM: To evaluate and compare the anatomical and functional outcomes and negative 
      effects of the three anti-vascular endothelial growth factor (VEGF) drugs in the 
      treatment of macular edema (ME) due to retinal vein occlusion (RVO) based on the 
      evidence pooled from current clinical trials and observational studies. METHODS: 
      A systematic literature search was conducted on nine online databases from 
      inception until April 30, 2022. The main endpoints were best corrected visual 
      acuity (BCVA), central macular thickness (CMT), and adverse events (AEs). 
      Cumulative Meta-analysis was conducted to synthesize the outcomes of the drugs. 
      The retrieved data were analyzed using Stata software (version 12.0). RESULTS: A 
      total of 20 studies comprising 1674 eyes met the inclusion criteria to the 
      Meta-analysis. It was observed that conbercept and aflibercept had better visual 
      acuity effects compared with ranibizumab at 1mo [weight mean difference 
      (WMD)=-0.03, P=0.001; WMD=-0.05, P=0.019], but the effects were not different 
      from that of ranibizumab at 6mo. Moreover, there was not statistically 
      significant difference in the proportion of patients gaining >/=15 letters at 
      12-24mo between aflibercept and ranibizumab [odds ratio (OR)=1.16, P=0.427]. 
      Conbercept had higher mean CMT change effects at 1mo (WMD=-14.43, P=0.014) and 
      6mo (WMD=-35.63, P</=0.001) compared with ranibizumab. Meanwhile, the mean CMT 
      change effects at 1mo (WMD=-10.14, P=0.170), 6mo (WMD=-26.98, P=0.140) and 
      12-24mo (WMD=-12.34, P=0.071) were comparable among the groups. Similarly, AEs 
      were not significantly different among the treatments (OR=0.75, P=0.305; OR=1.04, 
      P=0.89). The stability of effect size of mean BCVA and CMT improved with the 
      increase in sample size. Aflibercept and conbercept required fewer injections 
      compared with ranibizumab. CONCLUSION: This is the first study to evaluate the 
      efficacy and AEs of intravitreal administration of conbercept, ranibizumab, and 
      aflibercept in the treatment of RVO-ME. Intravitreal aflibercept or conbercept 
      results in better mean change in vision and CMT reduction compared with 
      ranibizumab. Conbercept can be considered to be a promising and innovative drug 
      with good anti-VEGF effects.
CI  - International Journal of Ophthalmology Press.
FAU - Xing, Qiu
AU  - Xing Q
AD  - Department of Ophthalmology, Central South University Xiangya School of Medicine 
      Affiliated Haikou Hospital, Haikou 570000, Hainan Province, China.
AD  - Department of Ophthalmology, the Second Xiangya Hospital of Central South 
      University, Changsha 410000, Hunan Province, China.
FAU - Dai, Ya-Nan
AU  - Dai YN
AD  - Department of Ophthalmology, the Changsha Central Affiliated Hospital, Hengyang 
      Medical School, University of South China, Changsha 410004, Hunan Province, 
      China.
FAU - Huang, Xiao-Bo
AU  - Huang XB
AD  - Department of Ophthalmology, Central South University Xiangya School of Medicine 
      Affiliated Haikou Hospital, Haikou 570000, Hainan Province, China.
FAU - Peng, Li
AU  - Peng L
AD  - Department of Ophthalmology, Central South University Xiangya School of Medicine 
      Affiliated Haikou Hospital, Haikou 570000, Hainan Province, China.
AD  - Department of Ophthalmology, the Second Xiangya Hospital of Central South 
      University, Changsha 410000, Hunan Province, China.
LA  - eng
PT  - Journal Article
DEP - 20230718
PL  - China
TA  - Int J Ophthalmol
JT  - International journal of ophthalmology
JID - 101553860
PMC - PMC10333252
OTO - NOTNLM
OT  - aflibercept
OT  - anti-vascular endothelial growth factor
OT  - conbercept
OT  - macular edema
OT  - ranibizumab
OT  - retinal vein occlusion
EDAT- 2023/07/19 06:43
MHDA- 2023/07/19 06:44
PMCR- 2023/07/18
CRDT- 2023/07/19 04:02
PHST- 2022/09/16 00:00 [received]
PHST- 2023/05/29 00:00 [accepted]
PHST- 2023/07/19 06:44 [medline]
PHST- 2023/07/19 06:43 [pubmed]
PHST- 2023/07/19 04:02 [entrez]
PHST- 2023/07/18 00:00 [pmc-release]
AID - ijo-16-07-1145 [pii]
AID - 10.18240/ijo.2023.07.21 [doi]
PST - epublish
SO  - Int J Ophthalmol. 2023 Jul 18;16(7):1145-1154. doi: 10.18240/ijo.2023.07.21. 
      eCollection 2023.